Document Detail


Niacin accelerates intracellular ApoB degradation by inhibiting triacylglycerol synthesis in human hepatoblastoma (HepG2) cells.
MedLine Citation:
PMID:  10195935     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The mechanism by which the potent drug niacin decreases apoB-containing atherogenic lipoproteins and prevents coronary disease is unclear. Utilizing human hepatoblastoma (HepG2) cells as an in vitro model, we have examined the effect of niacin on intracellular degradation of apoB and the regulatory mechanisms involved in apoB processing. Niacin significantly increased apoB degradation in a dose- and time-dependent manner. Treatment of HepG2 cells with calpain inhibitor I [N-acetyl-leucyl-leucyl-norleucinal (ALLN), an inhibitor of certain protease-mediated apoB degradation], did not alter niacin-induced apoB degradation. Niacin decreased inhibition of oleate-mediated apoB degradation. Niacin dose-dependently inhibited the synthesis of both fatty acids and triacylglycerol (TG) by 20% to 40% as determined by the incorporation of 14C-acetate and 3H-glycerol into fatty acids and TG, respectively. Incubation of HepG2 cells with niacin significantly inhibited (by 12% to 15%) fatty acid esterification to produce TG as assessed by the incorporation of 3H-oleic acid into TG. 14C-acetate incorporation into cholesterol and phospholipids was unchanged. The activity of microsomal triglyceride transfer protein (MTP), a carrier protein for lipids, was not altered by pretreatment of cells with niacin. ApoB mRNA expression and 125I-LDL protein uptake were also unchanged. These data indicate that niacin accelerates hepatic intracellular post-translational degradation of apoB by selectively reducing triglyceride synthesis (through inhibiting both fatty acid synthesis and fatty acid esterification to produce TG) without affecting ALLN-inhibitable protease- or MTP-mediated intracellular apoB processing, resulting in decreased apoB secretion and hence lower circulating levels of the atherogenic lipoproteins.
Authors:
F Y Jin; V S Kamanna; M L Kashyap
Related Documents :
12460405 - In vitro evaluation of newly developed adsorbent for selective removal of glycosylated ...
2253355 - Insufficient accuracy and specificity of polyanion precipitation methods for quantifyin...
17884995 - Cruciferous indole-3-carbinol inhibits apolipoprotein b secretion in hepg2 cells.
167855 - Effects of several common long chain fatty acids on the properties and lipid compositio...
806645 - Site of inhibitory action of isoniazid in the synthesis of mycolic acids in mycobacteri...
23495155 - Towards squalamine mimics: synthesis and antibacterial activities of head-to-tail dimer...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Arteriosclerosis, thrombosis, and vascular biology     Volume:  19     ISSN:  1079-5642     ISO Abbreviation:  Arterioscler. Thromb. Vasc. Biol.     Publication Date:  1999 Apr 
Date Detail:
Created Date:  1999-05-17     Completed Date:  1999-05-17     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9505803     Medline TA:  Arterioscler Thromb Vasc Biol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  1051-9     Citation Subset:  IM    
Affiliation:
Cholesterol Center, Medical Service, Department of Veterans Affairs Medical Center, Long Beach, CA, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Apolipoproteins B / biosynthesis,  genetics,  metabolism*
Hepatoblastoma / metabolism*,  pathology
Humans
Intracellular Fluid / drug effects,  metabolism*
Niacin / pharmacology*
Triglycerides / antagonists & inhibitors*,  biosynthesis*
Tumor Cells, Cultured
Chemical
Reg. No./Substance:
0/Apolipoproteins B; 0/Triglycerides; 59-67-6/Niacin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  NGF activates similar intracellular signaling pathways in vascular smooth muscle cells as PDGF-BB bu...
Next Document:  Effect of cardiopulmonary bypass and heparin on plasma levels of Lp(a) and Apo(a) fragments.